{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:57Z","timestamp":1791357297286,"version":"4.3.1"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Frontiers in Neuroendocrinology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.yfrne.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T07:34:04Z","timestamp":1487748844000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics"],"prefix":"10.1016","volume":"45","author":[{"given":"\u00c1ngel L.","family":"Montejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benidicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Del Pino-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Garc\u00eda-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Garc\u00eda-Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mart\u00edn-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn","family":"Mayoral-Cleries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Mayoral-van Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Mories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Pachiarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yfrne.2017.02.003_b0005","first-page":"223","article-title":"Valproate-associated reproductive hormone abnormalities: do bipolar men have the same risk as epileptic men?","volume":"23","author":"Aldemir","year":"2012","journal-title":"T\u00fcrk Psikiy. Derg."},{"issue":"Suppl. 2","key":"10.1016\/j.yfrne.2017.02.003_b0010","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65","author":"Alexopoulos","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","article-title":"Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Almandil","year":"2013","journal-title":"Paediatr. Drugs"},{"issue":"24","key":"10.1016\/j.yfrne.2017.02.003_b0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.22385","article-title":"Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists","volume":"15","author":"Andersohn","year":"2009","journal-title":"Mov. Disord. Jan."},{"key":"10.1016\/j.yfrne.2017.02.003_b0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.comppsych.2007.02.001","article-title":"Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group","volume":"48","author":"Ansell","year":"2007","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"Arakawa","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4088\/JCP.v65n0117","article-title":"An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction","volume":"65","author":"Aviv","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0040","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1176\/appi.ajp.159.12.2112","article-title":"Risperidone-induced hyperprolactinemia in an elderly woman","volume":"159","author":"Bai","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0045","first-page":"5","article-title":"Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder","volume":"47","author":"Bellantuono","year":"2012","journal-title":"Riv Psichiatr."},{"key":"10.1016\/j.yfrne.2017.02.003_b0050","first-page":"595","article-title":"The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine","volume":"42","author":"Barszcz","year":"2008","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0278-5846(00)00165-2","article-title":"Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder","volume":"25","author":"Ba\u015ft\u00fcrk","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"Suppl.","key":"10.1016\/j.yfrne.2017.02.003_b0060","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jad.2012.02.030","article-title":"Antipsychotics in pediatric and adolescent patients: a review of comparative safety data","volume":"138","author":"Ben Amor","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.yfrne.2017.02.003_b0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.rpsm.2012.11.001","article-title":"Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs)","volume":"6","author":"Bernardo","year":"2013","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rpsm.2011.07.003","article-title":"Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry","volume":"4","author":"Bernardo","year":"2011","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance","volume":"40","author":"Besnard","year":"2014","journal-title":"Encephale"},{"key":"10.1016\/j.yfrne.2017.02.003_b0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1888-9891(08)72513-8","article-title":"Spanish consensus on physical health of patients with bipolar disorder","volume":"1","author":"Bobes","year":"2008","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0085","article-title":"Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics","volume":"15","author":"Boggs","year":"2013","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.yfrne.2017.02.003_b0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yfrne.2017.02.003_b0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","article-title":"A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?","volume":"47","author":"Bushe","year":"2010","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.yfrne.2017.02.003_b0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00926230490465082","article-title":"An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction","volume":"30","author":"Byerly","year":"2004","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.yfrne.2017.02.003_b0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.yfrne.2017.02.003_b0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4088\/JCP.08m04595gre","article-title":"A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys","volume":"71","author":"Calarge","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00213-012-2880-0","article-title":"Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder","volume":"224","author":"Carrasco","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.yfrne.2017.02.003_b0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.20344\/amp.1415","article-title":"Hyperprolactinemia in mentally ill patients","volume":"24","author":"Carvalho","year":"2011","journal-title":"Acta Med. Port."},{"key":"10.1016\/j.yfrne.2017.02.003_b0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.genhosppsych.2007.11.002","article-title":"Cabergoline-induced psychotic exacerbation in schizophrenic patients","volume":"30","author":"Chang","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","article-title":"Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series","volume":"65","author":"Chen","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.yfrne.2017.02.003_b0160","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0165","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4088\/JCP.08l04671","article-title":"Aripiprazole treatment of risperidone-induced hyperprolactinemia","volume":"70","author":"Chen","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/11204840-000000000-00000","article-title":"Paliperidone extended release: a review of its use in the management of schizophrenia","volume":"70","author":"Chwieduk","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.yfrne.2017.02.003_b0175","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","article-title":"Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.yfrne.2017.02.003_b0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/104454601317261618","article-title":"Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children","volume":"11","author":"Cohen","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0185","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1192\/bjp.182.44.s3","article-title":"Epidemiology, public health and the problem of personality disorder","volume":"182","author":"Coid","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis","volume":"26","author":"Cookson","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"issue":"1\u20133","key":"10.1016\/j.yfrne.2017.02.003_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.yfrne.2017.02.003_b0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1872214807666131229125700","article-title":"Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole","volume":"8","author":"De Berardis","year":"2014","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/j.yfrne.2017.02.003_b0215","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAM- SEL Clinical Trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated Prolactin)","volume":"13","author":"Deanna","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.yfrne.2017.02.003_b0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rpsm.2014.07.005","article-title":"Bipolar disorders in the new DSM-5 and ICD-11 classifications","volume":"17","author":"de Dios","year":"2014","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0225","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0924-9338(10)71702-8","article-title":"Physical health management in psychiatric settings","volume":"25","author":"De Hert","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.yfrne.2017.02.003_b0235","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/2046-4053-3-116","article-title":"The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis","volume":"13","author":"Druyts","year":"2014","journal-title":"Syst. Rev."},{"key":"10.1016\/j.yfrne.2017.02.003_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000071823","article-title":"Decreased plasma prolactin release in euthymic lithium-treated women with bipolar disorder","volume":"48","author":"El Khoury","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.yfrne.2017.02.003_b0245","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.yfrne.2017.02.003_b0255","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archgenpsychiatry.2011.1508","article-title":"A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents","volume":"69","author":"Geller","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0260","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.rpsm.2014.05.003","article-title":"Spanish consensus on the physical health of patients with depressive disorders","volume":"7","author":"Giner","year":"2014","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0265","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/appi.ajp.163.3.494","article-title":"Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial","volume":"163","author":"Gopalakrishnan","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0270","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14740338.2011.560112","article-title":"Risk of osteoporosis and fracture incidence in patients on antipsychotic medication","volume":"10","author":"Graham","year":"2011","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.yfrne.2017.02.003_b0275","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1461145713001168","article-title":"Antipsychotic switching in bipolar disorders: a systematic review","volume":"17","author":"Grande","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0280","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.yfrne.2017.02.003_b0285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","article-title":"Gu\u00eda cl\u00ednica de diagn\u00f3stico y tratamiento del prolactinoma y la hiperprolactinemia","volume":"60","author":"Halperin","year":"2013","journal-title":"Endocrinol. Nutr."},{"key":"10.1016\/j.yfrne.2017.02.003_b0290","first-page":"1571","article-title":"The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study","volume":"10","author":"Hashimoto","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.yfrne.2017.02.003_b0295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.yfrne.2017.02.003_b0300","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881107087951","article-title":"Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists","volume":"22","author":"Holt","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0305","first-page":"95","article-title":"Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia","volume":"40","author":"Igarashi","year":"1985","journal-title":"Adv. Biochem. Psychopharmacol."},{"issue":"34","key":"10.1016\/j.yfrne.2017.02.003_b0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.pnpbp.2010.07.011","article-title":"Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia","volume":"1","author":"Ishitobi","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DHPS.S6226","article-title":"Safety and tolerability of antipsychotics: focus on amisulpride","volume":"2","author":"Juruena","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"10.1016\/j.yfrne.2017.02.003_b0320","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0325","first-page":"135","article-title":"Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia","volume":"25","author":"Kaneda","year":"2004","journal-title":"Neuro. Endocrinol. Lett."},{"key":"10.1016\/j.yfrne.2017.02.003_b0330","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)","volume":"13","author":"Kelly","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0335","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone","volume":"63","author":"Kim","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0340","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl. 2","key":"10.1016\/j.yfrne.2017.02.003_b0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.yfrne.2017.02.003_b0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1525-8610(04)70344-8","article-title":"The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients","volume":"4","author":"Kinon","year":"2003","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.yfrne.2017.02.003_b0355","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0360","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00737-010-0150-x","article-title":"Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature","volume":"13","author":"Kuloglu","year":"2010","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.yfrne.2017.02.003_b0365","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents","volume":"17","author":"Laita","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","article-title":"Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study","volume":"64","author":"Lee","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.yfrne.2017.02.003_b0375","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"1","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.yfrne.2017.02.003_b0380","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.4088\/JCP.v67n0922a","article-title":"A crossover study of prolactin changes associated with risperidone and olanzapine","volume":"67","author":"Lin","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"32","key":"10.1016\/j.yfrne.2017.02.003_b0385","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"12","author":"Lu","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0390","first-page":"107","article-title":"Actualizaci\u00f3n en esquizofrenia. Morbilidad m\u00e9dica en la esquizofrenia","volume":"B-32","author":"Man\u00e9","year":"2005","journal-title":"Barcelona: SCM, SL. Dep. legal:"},{"key":"10.1016\/j.yfrne.2017.02.003_b0395","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yfrne.2017.02.003_b0400","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0405","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.rpsm.2012.03.006","article-title":"Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results","volume":"5","author":"Merch\u00e1n-Naranjo","year":"2012","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0410","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","article-title":"Change in sexual dysfunction with aripiprazole: a switching or add-on study","volume":"22","author":"Mir","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0415","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4088\/JCP.v69n0206","article-title":"Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study","volume":"69","author":"Mitsonis","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0420","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","author":"Montejo","year":"2016","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.yfrne.2017.02.003_b0425","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1111\/j.1743-6109.2010.01709.x","article-title":"Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics","volume":"7","author":"Montejo","year":"2010","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.yfrne.2017.02.003_b0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/00926230701866125","article-title":"Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders","volume":"34","author":"Montejo","year":"2008","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.yfrne.2017.02.003_b0435","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/01.jcp.0000186872.04984.56","article-title":"A 6-month prospective observational study on the effects of quetiapine on sexual functioning","volume":"25","author":"Montejo","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0440","first-page":"13","article-title":"Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole","volume":"38","author":"Montejo","year":"2010","journal-title":"Actas Esp. Psiquiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.yfrne.2017.02.003_b0450","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.euroneuro.2008.02.004","article-title":"Prolactin awareness: an essential consideration for physical health in schizophrenia","volume":"18","author":"Montejo","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0455","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2005-837766","article-title":"Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia","volume":"38","author":"Nakajima","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0460","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/00926230701267829","article-title":"The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine","volume":"33","author":"Nakonezny","year":"2007","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.yfrne.2017.02.003_b0465","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/0092623X.2011.606883","article-title":"Strategies for the treatment of antipsychotic-induced sexual dysfunction and\/or hyperprolactinemia among patients of the schizophrenia spectrum: a review","volume":"38","author":"Nunes","year":"2012","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.yfrne.2017.02.003_b0470","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4088\/JCP.v67n0612","article-title":"Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine","volume":"67","author":"Papakostas","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0475","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0972-6748.90348","article-title":"Switching to quetiapine for risperidone-induced amenorrhea: report of two cases","volume":"19","author":"Pardal","year":"2010","journal-title":"Ind. Psychiatry J."},{"key":"10.1016\/j.yfrne.2017.02.003_b0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0269881103017002012","article-title":"Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients","volume":"17","author":"Paton","year":"2003","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0485","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0490","first-page":"121","article-title":"Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment","volume":"158","author":"Pollice","year":"2007","journal-title":"Clin. Ter."},{"key":"10.1016\/j.yfrne.2017.02.003_b0495","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2011.09.008","article-title":"Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder","volume":"22","author":"Popovic","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0500","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4088\/JCP.v65n1020b","article-title":"Cardiopulmonary complications of ergot-derivative dopamine agonists","volume":"65","author":"Rack","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0505","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-012-0009-0","article-title":"Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients","volume":"29","author":"Rado","year":"2012","journal-title":"Drugs Agin."},{"key":"10.1016\/j.yfrne.2017.02.003_b0510","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol. Med."},{"issue":"34","key":"10.1016\/j.yfrne.2017.02.003_b0515","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.pnpbp.2010.06.003","article-title":"Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia","volume":"16","author":"Rocha","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0520","doi-asserted-by":"crossref","DOI":"10.1186\/1687-9856-2010-159402","article-title":"Hyperprolactinemia with antipsychotic drugs in children and adolescents","author":"Rosenbloom","year":"2010","journal-title":"Int. J. Pediatr. Endocrinol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0525","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1743-6109.2012.02778.x","article-title":"Standard operational procedures for low sexual desire in men","volume":"10","author":"Rubio-Aurioles","year":"2013","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.yfrne.2017.02.003_b0530","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000054954","article-title":"Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients","volume":"45","author":"Sagud","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.yfrne.2017.02.003_b0535","first-page":"251","article-title":"Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry","volume":"36","author":"S\u00e1iz Ruiz","year":"2008","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.yfrne.2017.02.003_b0540","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study","volume":"193","author":"Schulz","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0545","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1542\/peds.2011-2158","article-title":"Antipsychotics for children and young adults: a comparative effectiveness review","volume":"129","author":"Seida","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.yfrne.2017.02.003_b0550","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0555","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/070674371105600702","article-title":"Psychiatric disorders in the elderly","volume":"56","author":"Skoog","year":"2011","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0560","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881115570083","article-title":"Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia","volume":"29","author":"Takase","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0565","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.schres.2013.04.015","article-title":"The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort","volume":"147","author":"Takahashi","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.yfrne.2017.02.003_b0570","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03345068","article-title":"Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders","volume":"23","author":"Tollin","year":"2000","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.yfrne.2017.02.003_b0575","first-page":"375","article-title":"Pituitary diseases in elderly patients with chronic renal insufficiency","volume":"57","author":"Vald\u00e9s Socin","year":"2002","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.yfrne.2017.02.003_b0580","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","article-title":"Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection","volume":"31","author":"van Kooten","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0585","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1017\/S1461145713000278","article-title":"Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd)","volume":"16","author":"Vieta","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"148","key":"10.1016\/j.yfrne.2017.02.003_b0590","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jad.2013.03.007","article-title":"Mixed states in DSM-5: implications for clinical care, education, and research","volume":"15","author":"Vieta","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.yfrne.2017.02.003_b0595","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JCP.0b013e31822c1636","article-title":"Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials","volume":"31","author":"Vita","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0600","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone","volume":"23","author":"Weiden","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0605","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1532-5415.1983.tb05123.x","article-title":"The correlation of increased serum prolactin levels with decreased sexual desire and activity in elderly men","volume":"31","author":"Weizman","year":"1983","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.yfrne.2017.02.003_b0610","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00004714-199706000-00025","article-title":"Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia","volume":"17","author":"Yamada","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0615","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0620","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2\u2217A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.yfrne.2017.02.003_b0625","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","article-title":"A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia","volume":"28","author":"Yuan","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2017.02.003_b0630","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","article-title":"Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection","volume":"33","author":"Ziadi Trives","year":"2013","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Frontiers in Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302217300092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302217300092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T09:28:01Z","timestamp":1692696481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091302217300092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":124,"alternative-id":["S0091302217300092"],"URL":"https:\/\/doi.org\/10.1016\/j.yfrne.2017.02.003","relation":{},"ISSN":["0091-3022"],"issn-type":[{"value":"0091-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Frontiers in Neuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yfrne.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}